ea0037gp.22.01 | Pituitary–Therapy of Cushing's disease | ECE2015
Shimatsu Akira
, Sauter Nicholas
, Kelly Roxzana
, Unge Peter
, Zhi Xin
, Fleseriu Maria
Introduction: Osilodrostat is a potent, oral inhibitor of 11β-hydroxylase, the enzyme that catalyses final step of cortisol biosynthesis. In a phase II study, 15/19 patients treated with osilodrostat met the primary endpoint (normal urinary free cortisol (UFC) at 22 weeks); osilodrostat was generally well tolerated. This phase III study aims to confirm the efficacy and long-term safety of osilodrostat.Patients and methods: Adults (1875 years) ...